geschrieben... Komisch dass der hier nicht in den News auftaucht...
Q2: not as strong as Q1, but still a very solid quarter Hypoport (HYQ) today (07 August) reported its final Q2 2017 figures, which were in line with the preliminary results announced at the end of July. Q2 revenues came in at € 47.6m, up 25% yoy, while EBIT was up 12% yoy to € 6.3m (Q2 2016: € 5.7m). EPS rose 18% yoy to € 0.87. Viewing H1 2017, revenues increased 29% yoy to € 95.3m, while EBIT was up 20% yoy to € 13.6m.Hypoport reiterated its full year guidance, i.e. low double-digit revenue and EBIT growth. H1 segment split: Institutional Clients segment with strongest growth (1) Institutional Clients showed the strongest growth with revenues up +36% and EBIT up +60% yoy in H1 2017. (2) Private Clients was also very strong with revenues +20% and EBIT +27%. (3) The Credit Platform (=Europace) posted solid top-line growth of +19% and EBIT up +13% yoy. The lower EBIT growth was mainly attributable to investments of € 0.5m in the new real estate appraisal business. (4) The new Insurance Tech segment grew its revenues to € 7.2m (H1 2016: € 1.2m), mainly due to acquisitions made in the last couple of months; EBIT was slightly negative at € -0.3m (after € -0.1m in Q1). Feedback from conference call The company held a conference call today at 14:00 CEST. Our key takeaways: Overall: Management’s tone was positive; operating momentum is likely to stay positive, in our view. Acquisitions: Management is currently looking at several potential acquisitions to strengthen the new insurance tech platform, and hinted that acquisitions are very likely in H2. The acquisitions should be similar in size to those done in the past, i.e. priced in the single-digit €m range. In this context management pointed out that the profit margins of companies in this segment are very low. It believes it can significantly increase these margins post-integration, i.e. management sees significant potential for value-creation through acquisitions. Genopace and Finmas perform strongly: In H1 2017, transaction volume on the platforms Genopace and Finmas increased 46% and 58% yoy, respectively (Q1 2017: up 52% and 63%), i.e. momentum again increased significantly in the market space where Europace is still relatively weak. (Continued on next page.) Buy rating and TP of € 139 reiterated We reiterate our Buy rating and our TP on Hypoport of € 139. For the Financial Service Providers segment we derive a fair value of €80.18/share; for the Private Clients segment €31.53/share; and for the Institutional Clients segment €14.13/share. To this we add a value of €12.53/share for the insurance tech business and deduct net debt of €0.12/share, which takes us to a fair value per share of €138.26. Our 2018e target P/E is 34.4x (EPS CAGR 2017-19e: 14.9%). Our TP is based on a mortgage market CAGR of 1.0% and an increase in Europace’s market share of 1.8pp per year. If we assume the growth rates of the past 5 years, i.e. 4% market CAGR and 2.2pp market share growth per year, we derive a DCF value of € 175.94/share (based on an assumption of 50% operating leverage).
https://www.hypoport.de/hypoport/uploads/2017/08/...-BHF_Hypoport.pdf
|